DIRS.INFO The most relevant business & tech news

☆ U.S. FDA grants priority review to Roche's bispecific antibody Glofitamab
▼ + stars: | 2023-01-06 | by ( ) www.reuters.com time to read: 1 min

ZURICH, Jan 6 (Reuters) - Roche (ROG.S) announced on Friday the U.S. Food and Drug Administration has granted priority review to the Swiss pharmaceutical company's bispecific antibody Glofitamab. Glofitamab is intended for patients with relapsed or refractory large b-cell lymphoma. The FDA is expected to make a decision on approval of the cancer immunotherapy by July 1, 2023. Reporting by Noele Illien; Editing by Tom HogueOur Standards: The Thomson Reuters Trust Principles.

☆ The FDA just approved a new Alzheimer's drug that's set to be a blockbuster
▼ + stars: | 2023-01-06 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +6 min

The FDA just approved a new treatment for Alzheimer's disease from Eisai and Biogen. Alzheimer's disease affects roughly 6.5 million Americans and has no cure. The FDA granted an accelerated approval of the drug, meaning the companies will have to conduct additional follow-up studies. While the drug has been approved, questions about cost remainWhile Leqembi has been approved by the FDA, the drug will have to face other key hurdles before it becomes widely available to patients. Aduhelm, an Alzheimer's drug also developed by Biogen and Eisai and approved by the FDA in 2021, failed to garner support from the Centers for Medicare and Medicaid Services, even after it was approved by the FDA.

☆ European shares head for best week since November, inflation data in focus
▼ + stars: | 2023-01-06 | by ( Bansari Mayur Kamdar | ) www.reuters.com time to read: +3 min

The pan-European STOXX 600 (.STOXX) was flat by 0915 GMT. For the week so far, it was up 3.4% following a drop in natural gas prices and upbeat economic data. All eyes are on the December euro zone inflation data due at 1000 GMT, with economists expecting prices to have declined year-on-year for a second consecutive month. "Inflation readings in the euro zone were not all good news, and core inflation remains high," analysts at UBS Global Wealth Management said in a note. "Despite the encouraging data (this week), we expect central banks to stick with a hawkish stance at this time."

☆ Biotech investor Brad Loncar shares 10 predictions for 2023, including a hot new cancer target, Nobel Prize winners, and a biotech founder running for president
▼ + stars: | 2023-01-04 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +14 min

Loncar shared his 2023 forecast, including new drugs, Nobel Prize winners, and more globalization. Brad Loncar isn't expecting a miraculous rebound for the biotech industry in 2023. In an interview with Insider, Loncar shared 10 predictions for biotech in 2023, ranging from Nobel Prize winners and presidential runs to hot cancer targets and bankruptcy worries. 2022 was a rough year for the biotech industry, which once again underperformed the stock market. The industry runs to the next super-hot cancer target: Claudin 18.2In cancer research, drug companies are always on the hunt for the next promising target.

☆ We're not near a bull market, David Roche says
▼ + stars: | 2023-01-03 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWe're not near a bull market, David Roche saysDavid Roche, president at Independent Strategy, says "we narrowly escaped recession."

☆ Brazilian soccer legend Pelé died of colon cancer. Here are the cutting-edge clinical trials trying to find new treatments for the disease.
▼ + stars: | 2022-12-30 | by ( Sarah Braner | ) www.businessinsider.com time to read: +4 min

The Brazilian soccer legend Pelé died of colon cancer Thursday at 82. Colon cancer is the third most common cancer, affecting almost 2 million people each year. Colorectal cancer is the third most common cancer, according to the World Cancer Research Fund International. Pelé isn't the only celebrity to have died of colon cancer in recent years — the Black Panther star Chadwick Boseman died of the disease in 2020 at the age of 43. Here are the cutting-edge phase-three clinical trials for colon cancer, in order of how recently they began.

☆ Pfizer's hemophilia B gene therapy succeeds in late-stage study
▼ + stars: | 2022-12-29 | by ( ) www.reuters.com time to read: +1 min

Dec 29 (Reuters) - U.S. drugmaker Pfizer Inc (PFE.N) said on Thursday its experimental gene therapy for the treatment of hemophilia B, a rare inherited blood disorder, met its main goal in a late-stage study. The drugmaker licensed its hemophilia B gene therapy from Roche's (ROG.S) Spark Therapeutics unit in 2014 for a $20-million upfront payment. Pfizer plans to discuss the late-stage data with regulatory authorities in Europe and the United States and share additional data for the experimental therapy at a scientific conference in early 2023. According to government data, the estimated prevalence of hemophilia in the United States is 12 cases per 100,000 males for hemophilia A and 3.7 cases per 100,000 males for hemophilia B. In November, the U.S. health regulator approved the first gene therapy, CSL Ltd and uniQure's Hemgenix, to treat hemophilia B.Pfizer is also testing other experimental gene therapies in late-stage trials as potential treatments for the bleeding disorder hemophilia A and muscular disorder Duchenne muscular dystrophy.

☆ 11 retinol and retinoid products for acne, wrinkles and more
▼ + stars: | 2022-12-28 | by ( Morgan Greenwald | Morgan Greenwald Is A Senior Editor For Select On Nbc News. | ) www.nbcnews.com time to read: +16 min

SKIP AHEAD Retinol and retinoid products | Retinol vs. retinoid | How to use retinol | What are the potential side effects of retinol? The serum contains time-released 1.5% retinol — which is on the higher side for retinol products — as well as vitamins C and E and squalane to moisturize the skin, according to the brand. Since retinoid products speeds up skin cell turnover, it can leave your skin feeling and looking dry, red and irritated. Greenwald has tried dozens of skin care products and brands over the years, including retinol products. Based on their guidance and recommendations, Greenwald reviewed the features and ingredients of highly rated retinoid products from brands like Neutrogena, Skinceuticals, Peter Thomas Roth, The Ordinary and more.

Dec 28 (Reuters) - TG Therapeutics Inc (TGTX.O) said on Wednesday that the U.S. health regulator had approved its monoclonal antibody for treating patients with relapsing forms of multiple sclerosis, sending its shares up nearly 9% in afternoon trade. TG Therapeutics said it was expecting to launch the drug, branded as Briumvi, in the first quarter of 2023, but did not give details on its pricing. Jefferies analyst Chris Howerton said ahead of the approval that he was expecting the drug to be priced in the range of $30,000 per patient per year. Multiple sclerosis is a neurological disease in which the immune system attacks the brain cells causing motor disabilities. Unlike other MS drugs that target T cells, Briumvi belongs to a class of drugs that tackles B cells' role in driving the inflammation that is central to neurological disease.

☆ Google will soon kill the cookie, and 2023 will be the year to show whether the technology invented to replace it can save the ad industry's revenue
▼ + stars: | 2022-12-22 | by ( Ryan Joe | ) www.businessinsider.com time to read: +7 min

The loss of the cookie and other ways to identify people online has caused ad revenue to crater. "Too soon to say, but the platforms don't like it," said David Temkin, a Google executive who focuses on ads privacy. "Clean rooms we think are promising because they can respect user privacy," Temkin said. He notes that clean rooms can be slow and expensive. The prevalence of retail media already jumpstarted the need for clean rooms in 2022, said Scott Howe, CEO of LiveRamp, which provides clean rooms and identifiers.

☆ Australian stock exchange's blockchain failure burns market trust
▼ + stars: | 2022-12-20 | by ( Byron Kaye | ) www.reuters.com time to read: +11 min

That 96% of that software is working," Hogben told a Stockbrokers and Investment Advisers Association conference, in footage seen by Reuters. More than a dozen brokers, other market participants and people directly involved in the blockchain project told Reuters the failure had shaken trust in the Australian exchange operator. After New York startup Digital Asset Holdings showed ASX executives a test transaction on its blockchain software, ASX in early 2016 signed the little-known company to begin exploratory work on an overhaul. From an initial plan to run about 12 of CHESS's 400 data transfers per transaction on blockchain, ASX decided the new system would include all 400 transfers, the person said. Its spokesperson told Reuters there was "no off-the-shelf solution available to meet the needs of the Australian market".

☆ Big Pharma will find right formula for M&A binge
▼ + stars: | 2022-12-20 | by ( Aimee Donnellan | ) www.reuters.com time to read: +3 min

The year 2022 was relatively thin for pharma M&A, with deals worth nearly $66 billion being announced by early December – 60% below the 9-year average, according to Refinitiv data; 2023 will be better. It helps that drug companies are relatively healthy, with debt around just 1.6 times forecast EBITDA in 2023, according to Berenberg analysts. Seagen (SGEN.O), for example, worth $22 billion in early December, has fought off Merck & Co (MRK.N). That puts Big Pharma in an ideal negotiating position. CONTEXT NEWSGlobal pharmaceutical companies spent nearly $66 billion on takeovers in 2022, according to data from Refinitiv as of Dec. 7.

Earlier, much smaller U.S. studies conducted in the mid-1980's had suggested roughly 60,000 people are diagnosed with Parkinson's disease each year. The estimated economic cost is $52 billion annually in the United States alone, according to a report of the study published in npj Parkinson's Disease. Fox Foundation for Parkinson's Research obtain increased funding for research and access to care. A separate study by Beck's team recently put the number of U.S. patients living with Parkinson's disease at nearly 1 million, whereas earlier estimates had been closer to 650,000, he said. "Because the U.S. population is aging, a lot of people are going to be entering the health system with Parkinson's disease," Beck said, "and there are only about 700 neurologists in the country who specialize in movement disorders."

☆ Roche's head of pharmaceuticals to leave company
▼ + stars: | 2022-12-12 | by ( ) www.reuters.com time to read: +1 min

ZURICH, Dec 12 (Reuters) - Roche's (ROG.S) head of its pharmaceuticals division will leave the drugmaker at the end of the year, the Swiss company said on Monday, as it confirmed other parts of its succession plan. Former Genentech boss Bill Anderson "has decided to pursue opportunities outside of Roche," Roche said, with a successor due to be named by March 2023. Schinecker will replace Severin Schwan, who is slated to become chairman after 14 years as CEO of Roche. He has been instrumental in shaping Roche’s transformation and I wish him all the best for the future," Schwan said in a statement. He had been CEO of Roche's pharmaceuticals business since 2019.

☆ U.S. prints its first-ever currency with two women's signatures on them
▼ + stars: | 2022-12-08 | by ( ) www.nbcnews.com time to read: +3 min

U.S. Treasury Secretary Janet Yellen will honor fellow pioneers when she presides over Thursday’s unveiling of the first U.S. banknotes printed with two women’s signatures, while calling for “much more” work to advance equity for women and minorities. The Fort Worth facility — one of two in the United States — prints over 50% of U.S. paper currency each year. “We’ve made progress in providing greater economic opportunity for women at Treasury and in the economics profession. It means a lot to me and my colleagues that she will be the first female Treasury secretary with her signature on the dollar note,” she said. “It represents that we are finally getting the insight from important parts of our economy and our society,” she said.

☆ Yellen honors fellow pioneers as U.S. prints first banknotes with two women's signatures
▼ + stars: | 2022-12-08 | by ( Andrea Shalal | ) www.reuters.com time to read: +2 min

FORT WORTH, Texas, Dec 8 (Reuters) - U.S. Treasury Secretary Janet Yellen will honor fellow pioneers when she presides over Thursday's unveiling of the first U.S. banknotes printed with two women's signatures, while calling for "much more" work to advance equity for women and minorities. The Fort Worth facility - one of two in the United States - prints over 50% of U.S. paper currency each year. "We’ve made progress in providing greater economic opportunity for women at Treasury and in the economics profession. But we know that much more needs to be done," Yellen said in remarks prepared for the event. "It represents that we are finally getting the insight from important parts of our economy and our society," she said.

☆ Yellen honors pioneers as U.S. prints first banknotes with women's signatures
▼ + stars: | 2022-12-08 | by ( Andrea Shalal | ) www.reuters.com time to read: +4 min

REUTERS/Shelby TauberFORT WORTH, Texas, Dec 8 (Reuters) - U.S. Treasury Secretary Janet Yellen on Thursday hailed fellow pioneers during the unveiling of the first U.S. banknotes printed with two women's signatures, while calling for "much more" work to advance equity for women and minorities. Seeing the bills for the first time, Yellen told Malerba: "Oh my gosh. Asked how she felt, a beaming Yellen told reporters: "Excited. But we know that much more needs to be done," Yellen told printers after a tour of the 675-person facility. It means a lot to me and my colleagues that she will be the first female Treasury secretary with her signature on the dollar note," she said.

☆ Lyon's Festival of Lights goes energy lite to save power
▼ + stars: | 2022-12-08 | by ( ) www.reuters.com time to read: +2 min

[1/7] The art installation "Time" by Philippe Roca and Marko Komar is seen on the Saint-Jean Cathedral during the festival of lights (Fetes des Lumieres) amid a worldwide energy crisis in Lyon, France, December 7, 2022. REUTERS/Denis BalibouseLYON, Dec 8 (Reuters) - Lyon's 'Fete des Lumieres', or Festival of Lights, which features intricate light structures projected on historical monuments and public buildings across town, is toning things down a bit this year due to the energy crisis, organisers said. Lyon locals Beatrice Roche and Laurent Oger attend the festival every year. 'La Fete des Lumieres', originally a festival in which locals celebrate the Virgin Mary by putting a candle on their window sills, attracts large crowds of visitors from all over the world. This year, one of the artworks is the projection on Lyon's art museum of giant portraits singing, among others, Britney Spears and AC/DC songs.

As the COP15 biodiversity summit kicks off in Montreal, businesses and corporate leaders are pushing for an ambitious agreement with strong policies that will provide guidance to companies seeking to change. They are under increasing pressure to show progress in tackling climate change and reducing harm to the environment. The agency has said some $384 billion will be needed each year for nature projects by 2025. "If we take that mindset to nature, it leads to the investment models that would allow us to invest in nature as infrastructure," he said. "Two years ago, all these governments around the world said 'let's put trillions of dollars into nature.'

☆ FDA Takes Tougher Line on Fast-Tracked Drugs
▼ + stars: | 2022-12-05 | by ( Liz Essley Whyte | ) www.wsj.com time to read: 1 min

The Food and Drug Administration sometimes clears prescription medicines based on preliminary data but asks makers to conduct follow-up confirmatory studies. The Food and Drug Administration is taking a harder line on its program that fast-tracks drug approvals based on preliminary evidence, spurring GSK PLC, Roche Holdings AG and other drugmakers to remake plans for their drugs or pull them from the market. Under the accelerated-approval program, the FDA clears the use of prescription medicines faster than it normally would. The agency relies on preliminary data to make the decision, but asks companies to conduct follow-up studies to confirm that the drug works.

☆ Rare success for Alzheimer's research unlocks hope for future therapies
▼ + stars: | 2022-11-29 | by ( Julie Steenhuysen | ) www.reuters.com time to read: +6 min

Eisai and Biogen are scheduled to present full data from their lecanemab study on Tuesday at the Clinical Trials on Alzheimer's Disease conference in San Francisco. Lecanemab’s success rests on years of research into the causes of Alzheimer’s as well as advances in measuring amyloid deposits through brain scans and spinal fluids. At least 16 treatments are being tested in clinical trials, with results expected over the next three years, according to a Reuters review of the clinicaltrials.gov registry. The drugmaker has been largely absent from the Alzheimer's space after the high-profile failure of its drug verubecestat five years ago. But several antibody therapies from Lilly, Biogen and AbbVie(ABBV.N) that were designed to slow the rate of tau accumulations failed outright last year.

☆ Outperforming asset manager picks the stocks set to win as margins get squeezed
▼ + stars: | 2022-11-25 | by ( Zavier Ong | ) www.cnbc.com time to read: +3 min

"Consumers are going to have their purse strings pulled by utility bills, higher mortgage costs, higher petrol prices, and there's going to be margin squeeze." He said wage pressure and higher commodity prices were particularly challenging and could eat into companies' margins. Luxury Luxury stocks are another favorite for Armstrong. Moreover, the "massive" profit margins of luxury companies are also insulated from increases in input prices, he added. Within the space, Armstrong's fund owns French luxury goods companies LVMH and Hermes , given their "defendable margins" and the ability to be price setters.

☆ This 31-year-old CEO says staying focused on one disease was the key to helping his company raise $120 million in a frozen biotech market
▼ + stars: | 2022-11-18 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +6 min

Arthur Kuan is the 31-year-old CEO of CG Oncology, a startup focused on treating bladder cancer. CG announced earlier this week that it has raised $120 million, despite a difficult biotech market. Since 2016, the year that Kuan became the CEO of CG Oncology, the Irvine, California-based cancer startup has raised big rounds from investors. "I think I've seen a lot of successful stories where you've stayed very focused on just one thing and you just see things that others don't by being very deep," Kuan told Insider. But when his father died that same year from pancreatic cancer, Kuan said he decided to focus on bladder cancer.

☆ No China is no fix for Britain’s industrial woes
▼ + stars: | 2022-11-17 | by ( ) www.reuters.com time to read: +2 min

LONDON, Nov 17 (Reuters Breakingviews) - The British government has blocked the sale of a silicon wafer factory in Wales to a subsidiary of China’s Wingtech Technology (600745.SS). It’s a sign of the growing wariness among western governments of the risks involved in Chinese investment. The decision to force Netherlands-based Nexperia to sell most of its stake in the Newport Wafer Fab business isn’t illogical. The plant makes basic silicon wafers, used in chips for switches in domestic appliances such as vacuum cleaners. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

☆ Target is hurting more than American consumers
▼ + stars: | 2022-11-16 | by ( ) www.reuters.com time to read: +2 min

NEW YORK, Nov 16 (Reuters Breakingviews) - The devil is in the details of Target’s (TGT.N)hellish run. Target is partly hostage to what’s on the shelves, including apparel, electronics and other discretionary items. Rival Walmart (WMT.N), which generates more than half its sales from food, delivered better results on Tuesday. The U.S. Commerce Department just reported that retail sales grew 1.3% in October from September because consumers were buying cars, furniture and clothes. Those numbers suggest that Target is hurting more than American shoppers.

Search resuls for: "Roche"

25 mentions found